4DMedical, the leader in software-based respiratory imaging technology, today announced US$100+ million (AU$150 million) in new institutional placement. The investment will primarily be leveraged to accelerate U.S. adoption of its class-leading “CT:VQ™” product and significantly boost research and development—bolstering 4D’s technology lead in software-based lung imaging.
CT:VQ™ is 4DMedical’s FDA-cleared, SaaS technology that provides ventilation and perfusion insights from CT imaging. Within just four months of FDA clearance, CT:VQ was deployed by four elite U.S. academic medical centers: Stanford, Cleveland Clinic, University of Miami, and UC San Diego Health. These rapid adoptions reflect growing interest from clinicians seeking quantified, actionable and functional information not available from traditional imaging–but increasingly vital to support diagnosis, treatment planning, and longitudinal monitoring.
Read More – Compa Raises $35M in Series B Funding
“This is an extraordinarily important and validating event for multiple reasons,” says Andreas Fouras, PhD, 4DMedical Founder and CEO. “First, it reflects growing global recognition of the technological leadership of 4DMedical, including our groundbreaking products such as CT:VQ™. And it recognizes both the commercial progress and even greater growth potential we have in the U.S. With this strong institutional backing and a strengthened balance sheet, we will scale adoption, accelerate R&D, deepen partnerships, and dominate the global marketplace for software-based lung imaging tools.”
What the funding enables for hospitals and health systems
4DMedical will use the funding to expand U.S. availability of CT:VQ™ and support health systems with implementation at scale, including:
- Commercial expansion across U.S. academic medical centers and health systems, with a focus on real-world adoption and multidisciplinary use
- Customer success, training, and technical support to help integrate CT:VQ™ into existing clinical workflows and drive consistent utilization
- Ongoing research and development to expand 4DMedical’s technology leadership, product portfolio and capabilities in functional lung imaging
- Operational scale and flexibility to support additional growth opportunities and sustained clinical partnerships
Following the raise, 4DMedical reported a pro forma cash position exceeding US$130+ million (AU$200+ million), which will support the company’s U.S. expansion strategy and growing installed base.
Built to integrate into clinical workflows
4DMedical’s products are delivered through a Software-as-a-Service (SaaS) model designed to integrate with existing hospital infrastructure. The company also highlighted strategic partnerships, including with Philips, aimed at supporting broader adoption pathways.
Read More – CVector Raises $5M in Seed Funding
